Compare TSCO & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSCO | INSM |
|---|---|---|
| Founded | 1938 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3B | 23.0B |
| IPO Year | 1996 | 2000 |
| Metric | TSCO | INSM |
|---|---|---|
| Price | $29.72 | $99.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 24 |
| Target Price | $53.05 | ★ $201.17 |
| AVG Volume (30 Days) | ★ 13.7M | 4.4M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | ★ 0.98 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $15,524,046,000.00 | N/A |
| Revenue This Year | $7.32 | $182.31 |
| Revenue Next Year | $6.01 | $65.19 |
| P/E Ratio | $97.55 | ★ N/A |
| Revenue Growth | ★ 4.31 | N/A |
| 52 Week Low | $28.36 | $90.39 |
| 52 Week High | $63.99 | $212.75 |
| Indicator | TSCO | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 38.34 | 42.65 |
| Support Level | $29.15 | $98.90 |
| Resistance Level | $31.96 | $166.81 |
| Average True Range (ATR) | 1.05 | 5.30 |
| MACD | 0.24 | 1.11 |
| Stochastic Oscillator | 41.77 | 57.72 |
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,395 of its namesake banners in 49 states, along with 207 Petsense by Tractor Supply stores. Stores are generally concentrated in rural communities rather than urban and suburban areas. In fiscal 2025, revenue consisted primarily of livestock, equine & agriculture (around 30%), companion animal (25%), and seasonal & recreation (around 25%).
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.